Modular Medical, traded on Nasdaq under the ticker MODD, is gearing up to revolutionize insulin delivery by transitioning its manufacturing line to produce the next generation of insulin pumps. The company recently completed the production run of its MODD1 product cartridge, marking a crucial step towards the production of its innovative Pivot product. Pivot, Modular Medical’s latest insulin patch pump technology, is designed to streamline diabetes care, particularly targeting adults who are new to insulin pumps with its user-friendly and cost-effective design.
The MODD1 pump, which received FDA clearance nearly a year ago, boasts microfluidics technology that enables the cost-efficient pumping of insulin. With a reservoir size of 300 units/3mL, the pump allows users to conveniently monitor its activity using a smartphone without the need for an external controller. Moreover, the pump operates on a single-use, disposable battery, enhancing convenience and usability for patients.
Modular Medical recently achieved a significant milestone by validating its insulin pump cartridge line for human-use production in the U.S. The company also reported the successful first human use of the MODD1 pump, further solidifying its position in the market. Looking ahead, Modular Medical is focused on advancing towards the launch of its next-gen pump, Pivot, with plans for FDA submission in October. Pivot is set to be the first tubeless, removable three-milliliter patch available to consumers, promising a new level of convenience and flexibility in insulin delivery.
Jeb Besser, CEO of Modular Medical, commended the operational team for the successful validation of the MODD1 manufacturing process and the production of human use cartridges. The company is now poised to transition its cartridge line to Pivot production, anticipating readiness to produce cartridges for the Pivot product pending FDA clearance. Besser emphasized the importance of scalability in the pump market, particularly for patch pumps that require significantly higher production volumes. Modular Medical’s platform, designed for high-volume manufacturing from the ground up, positions the company as a key player in the evolving landscape of insulin delivery technology.
In the competitive landscape of diabetes care and drug-device combinations, Modular Medical’s innovative approach to insulin pump technology sets it apart. By focusing on user-friendly design, cost-efficiency, and scalability, the company is well-positioned to capture a significant share of the market and cater to the evolving needs of patients with diabetes. As Modular Medical progresses towards the commercialization of Pivot and expands its product portfolio, investors and stakeholders can anticipate exciting developments in the field of insulin delivery technology.
- Modular Medical is making significant strides in insulin pump technology, with the imminent production of its next-gen Pivot pump set to transform diabetes care.
- The company’s focus on user-friendly design and cost-efficiency, coupled with its emphasis on scalability, positions it as a key player in the evolving market.
- Achieving milestones such as FDA clearance and successful human trials underscores Modular Medical’s commitment to innovation and excellence in insulin delivery.
- With a strong leadership team and a clear roadmap for product development, Modular Medical is poised for success as it advances towards commercializing its cutting-edge insulin pump technology.
Tags: microfluidics, drug delivery
Read more on drugdeliverybusiness.com